Artal Group’s LAVA Therapeutics LVTX Stock Holding History

Artal Group’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-200,000	Closed	-$294K	–	105
2023 Q3	$294K	Hold	200,000	–	–	0.01%	92
2023 Q2	$406K	Hold	200,000	–	–	0.01%	106
2023 Q1	$332K	Hold	200,000	–	–	0.02%	108
2022 Q4	$700K	Hold	200,000	–	–	0.04%	112
2022 Q3	$914K	Hold	200,000	–	–	0.04%	116
2022 Q2	$590K	Hold	200,000	–	–	0.03%	119
2022 Q1	$880K	Hold	200,000	–	–	0.04%	126
2021 Q4	$1.1M	Hold	200,000	–	–	0.03%	139
2021 Q3	$1.18M	Hold	200,000	–	–	0.03%	140
2021 Q2	$2.18M	Hold	200,000	–	–	0.04%	136
2021 Q1	$3.04M	Buy	+200,000	New	+$2.75M	0.05%	133

Other funds holding LVTX

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Artal Group's LVTX Position: Q4 2023 in Review

Artal Group sold out of LAVA Therapeutics (LVTX) in Q4 2023, closing a stake of 200,000 shares — an estimated $294K sold.

Artal Group first reported a position in LVTX in Q1 2021 and held it in 11 quarters. The position peaked at $3.04M in Q1 2021. 14 funds tracked by Wall St. Rank hold LVTX as of Q4 2023.

Artal Group reported no remaining LAVA Therapeutics position as of Q4 2023 after selling out during the quarter.
Artal Group sold 200,000 LAVA Therapeutics shares in Q4 2023, an estimated $294K.
Artal Group first reported a position in LAVA Therapeutics in Q1 2021 and held it in 11 quarters.
Artal Group's LAVA Therapeutics position peaked at $3.04M in Q1 2021.
14 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2023.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.